Navigation Links
Vasogen Announces Third Quarter 2008 Results
Date:10/15/2008

MISSISSAUGA, ON, Oct. 15 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today reported the results of operations for the three and nine months ended August 31, 2008. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted.

At August 31, 2008, our cash and cash equivalents totaled $9.8 million, compared with $12.4 million at May 31, 2008.

The net loss for the third quarter of 2008 was $2.6 million, or $0.12 per common share, compared with a net loss of $5.3 million, or $0.24 per common share for the same period in 2007. We incurred a net loss for the nine months ended August 31, 2008 of $15.3 million, or $0.68 per common share, compared with a net loss of $22.7 million, or $1.21 per common share for the same period in 2007. Our net loss included restructuring costs for the three months and nine months ended August 31, 2008 of $0.8 million and $3.1 million, respectively. In addition to the cost savings from the termination of our lease, as discussed below, we expect a further reduction of infrastructure and other support costs associated with the facility.

A key driver of our decreased loss in both these periods was lower salary and benefit costs, reduced stock compensation expense, lower infrastructure and other support costs driven by lower employee numbers in 2008, and a decrease in the foreign exchange loss that was incurred in the prior periods. In addition, during the nine months ended August 31, 2008, the decrease was impacted by a reduction in expenses resulting from the repayment of the senior convertible notes in April 2007.

Corporate Update

- On July 3, 2008, we announced the implementation of additional

restructuring plans to further
'/>"/>

SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vasogen Announces Third Quarter Conference Call and Webcast of Bio InvestorForum 2007 Presentation
2. Vasogen Announces Third Quarter 2007 Results
3. Vasogen to Webcast Presentations at Three Upcoming Healthcare Conferences
4. Vasogen Provides an Update on ACCLAIM-II Preparations
5. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
6. Vasogen to Conduct Year-end 2007 Conference Call
7. Vasogen Announces 2007 Year-End Results
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogens Research Published in European Journal of Neuroscience
10. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
11. Vasogen Provides Update on ACCLAIM II Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , September 2, 2015 ... primär auf die Forschung und Entwicklung neuartiger ... Allergien, chronisch-entzündliche Darmerkrankungen und Reizdarm konzentriert, erhält ... Zusage, dass sein neues Medikament patentiert wird. ... das Allergien bei Kindern verhindert und Entzündungen ...
(Date:9/1/2015)... 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Annual Global Investment Conference sponsored by H.C. ... at The St. Regis Hotel in New ... Sapirstein , Chief Executive Officer, will provide an overview ...
(Date:9/1/2015)... ... 01, 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine ... future faced with an Ebola pandemic that is on the cusp of wiping out ... the world of counterterrorism, and who continues to appear in this series of books ...
(Date:9/1/2015)... 1, 2015 The Dohmen Company today ... Ph.D., MBA as Chief Science Officer (CSO) of ... created role, Dr. Floyd will lead Dohmen,s growing ... of pre-commercial and post approval outsourced services in ... communications.  Dr. Floyd brings decades of experience leading ...
Breaking Biology Technology:Das Patent von Swecure zur Verhinderung von Allergien bei Kindern wird in den USA zugelassen 2ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3
... A team led by Johns Hopkins researchers has solved ... of bacteria, discoveries that could lead to a new ... in the journal Current Biology, the scientists reported how ... a rod-shaped bacterium to produce two offspring, can be ...
... Colo., April 8, 2008 HemoGenix(R),Inc., a privately-held ... USPTO has issued the first two of several ... the 21st,century answer and the only alternative to, ... first described in 1966., HALO(R) was developed ...
... ShapeGrabber and Nikon,Instruments Inc. today announced ... a,sales distribution channel in the United States ... inspection systems. This arrangement will,increase ShapeGrabber,s current ... Nikon to provide customers with,additional non-contact solutions ...
Cached Biology Technology:Solving the Z ring's mysteries may lead to new antibiotics 2Solving the Z ring's mysteries may lead to new antibiotics 3HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO). 2HemoGenix(R), Inc. Receives Issued Patent for its HALO(R) Technology Platform From the United States Patent and Trademark Office (USPTO). 3ShapeGrabber and Nikon Instruments Inc. Announce Distribution Agreement 2
(Date:8/19/2015)... , Aug. 19, 2015  VOXX International Corporation ... has entered into a Definitive Agreement to purchase ... iris authentication market leader EyeLock through an acquiring ... have a controlling interest in the acquiring entity. ... completion of due diligence.  Expanding on its existing ...
(Date:8/12/2015)... As the digital payment services ... advanced biometrics technology is accelerating beyond expectations.  While the ... using their credit cards, the digital currency, mobile payment ... services led by companies in the space such as ... (NASDAQ: GOOG ), Apple Inc. (NASDAQ: AAPL ...
(Date:8/10/2015)... -- The latest 364 page report from business ... global border security market . Visiongain assesses ... Now: Border security is hard to achieve and ... critical issue you need to know about - and more ... of how this will impact your company and the border ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 2Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 3Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 4Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 5Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 6Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 7Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 8Border Security Market Report 2015-2025 - Growth in Biometrics, ICT, Manned and Unmanned Vehicles, and Perimeter Surveillance 9
... with irreparable DNA damage normally induce programmed cell death, ... tumor cells so that transformed cells are able to ... German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now ... simply degrade a protein that triggers apoptosis in the ...
... Blue Tongue virus has been created by WMG engineering researchers ... new ways to combat the virus and protect millions of ... researchers based their model on data provided by the Institute ... Warwick team used rapid prototyping technology, normally used to ...
... over a decade, the drug called tPA has proven its ... common kind of stroke. But its promise is blemished by ... and its brain-saving power fades fast after the third hour ... in Nature Medicine reveals why tPA has these ...
Cached Biology News:Refusal of suicide order: Why tumor cells become resistant 2Engineers create 3-D model to help biologists combat blue tongue virus 2Stroke study reveals key target for improving treatment and suggests that Gleevec may help 2Stroke study reveals key target for improving treatment and suggests that Gleevec may help 3Stroke study reveals key target for improving treatment and suggests that Gleevec may help 4
AVOID FREEZE/THAW CYCLES. Recognizes the ~32 kDa DNase IIα chain and the ~40 kDa proenzyme. DNase II causes both DNA condensation and DNA fragmentation. ...
BD BioCoat Vented Caps for 175 cm2 Flasks...
...
I-Ab MHC Class II...
Biology Products: